• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Indivior PLC

    5/22/25 4:45:47 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INDV alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)


    INDIVIOR PLC

    (Name of Issuer)


    Ordinary Shares, $0.50 nominal value per share

    (Title of Class of Securities)


    G4766E116

    (CUSIP Number)


    Lawrence V. Palermo
    Two Seas Capital LP, 32 Elm Place, 3rd Floor
    Rye, NY, 10580
    (646) 420-4504

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    05/20/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    G4766E116


    1 Name of reporting person

    Two Seas Capital LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    11,880,926.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    11,880,926.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    11,880,926.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.5 %
    14Type of Reporting Person (See Instructions)

    IA, PN



    SCHEDULE 13D

    CUSIP No.
    G4766E116


    1 Name of reporting person

    Two Seas Capital GP LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    11,880,926.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    11,880,926.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    11,880,926.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.5 %
    14Type of Reporting Person (See Instructions)

    HC, OO



    SCHEDULE 13D

    CUSIP No.
    G4766E116


    1 Name of reporting person

    Sina Toussi
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    11,880,926.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    11,880,926.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    11,880,926.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.5 %
    14Type of Reporting Person (See Instructions)

    IN, HC



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Ordinary Shares, $0.50 nominal value per share
    (b)Name of Issuer:

    INDIVIOR PLC
    (c)Address of Issuer's Principal Executive Offices:

    10710 Midlothian Turnpike, Suite 125, North Chesterfield, VIRGINIA , 23235.
    Item 1 Comment:
    The following constitutes Amendment No. 6 ("Amendment No. 6") to the Schedule 13D filed with the Securities and Exchange Commission ("SEC") by Two Seas Capital LP ("TSC"), Two Seas Capital GP LLC ("TSC GP") and Sina Toussi (collectively, the "Reporting Persons") on October 2, 2023, as amended by Amendment No. 1 filed on March 29, 2024, Amendment No. 2 filed on June 21, 2024, Amendment No. 3 filed on October 17, 2024, Amendment No. 4 filed on January 17, 2025, and Amendment No. 5 filed on March 4, 2025. This Amendment No. 6 amends and supplements the Schedule 13D as specifically set forth herein. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D, as amended. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Item 3 of the Schedule 13D is hereby amended and restated as follows: The aggregate purchase price of the 8,518,026 Ordinary Shares directly held by the Litigation Fund reported herein was approximately $69,877,663. The aggregate purchase price of the 3,362,900 Ordinary Shares directly held by the Global Fund reported herein was approximately $32,660,043. The Ordinary Shares directly held by the Funds were purchased with the working capital of the Funds (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) and proceeds from the Credit Facility (the "Credit Facility") for the Litigation Fund, provided by UBS AG, London Branch ("UBS"), pursuant to the Credit Facility Agreement, by and between, the Litigation Fund, as Borrower, and UBS, acting as Lender, dated June 16, 2022, as amended and restated on September 22, 2022, on April 5, 2023, and on June 19, 2023, as amended on December 20, 2023, as amended and restated by the Fifth Amendment Agreement dated June 20, 2024, and as amended and restated on December 20, 2024, by the Sixth Amendment Agreement (the "Credit Facility Agreement").
    Item 5.Interest in Securities of the Issuer
    (a)
    (a) Each of the Reporting Persons may be deemed to beneficially own 11,880,926 Ordinary Shares of the Issuer, which represents approximately 9.5% of the Ordinary Shares outstanding, based on 124,769,533 Ordinary Shares of the Issuer outstanding as of May 1, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on May 1, 2025. The Funds have delegated to TSC sole voting and investment power over the securities held by the Funds pursuant to their respective Investment Management Agreements with TSC. As a result, each of TSC, TSC GP, as the general partner of TSC, and Mr. Toussi, as Chief Investment Officer of TSC and Managing Member of TSC GP, may be deemed to exercise voting and investment power over the Ordinary Shares directly held by the Funds. The Funds specifically disclaim beneficial ownership of the securities of the Issuer directly held by them by virtue of their inability to vote or dispose of such securities as a result of their respective Investment Management Agreements with TSC. The information in Item 3 regarding the number of Ordinary Shares held by the Funds is incorporated herein by reference.
    (b)
    Items 7 through 10 of each of the cover pages of this Schedule 13D are incorporated herein by reference.
    (c)
    Transactions by the Reporting Persons (on behalf of the Funds) effected during the past 60 days are set forth in Exhibit 99.1 and such information is incorporated herein by reference.
    (d)
    The disclosure regarding the relationship between the Reporting Persons in Item 2(c) of this Schedule 13D is incorporated herein by reference. All securities reported in this Schedule 13D are directly held by the Funds, each of which are investment management clients of TSC. The limited partners of (or investors in) each of the Funds have the right to participate in the receipt of dividends from, or proceeds from the sale of, the Ordinary Shares held for the accounts of their respective Funds in accordance with their respective limited partnership interests (or investment percentages) in their respective Funds.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    Item 6 of this Schedule 13D is supplemented and superseded, as the case may be, as follows: Pursuant to the Security Agreement, dated June 16, 2022, by and between the Litigation Fund, as Grantor, and UBS, as Secured Party, as amended (the "Security Agreement"), the Litigation Fund has pledged to UBS 8,159,854 Ordinary Shares held by it, subject to potential adjustments agreed upon by the parties from time to time. If the Litigation Fund defaults on its obligations under the Credit Facility Agreement, such default could result in foreclosure proceedings against the Ordinary Shares pledged as collateral by the Litigation Fund, subject to a beneficial ownership limitation. The pledged Ordinary Shares are subject to certain transfer restrictions. The total commitment under the Credit Facility was fully drawn and a loan amount of $7,000,000 that was drawn remains outstanding, subject to potential adjustments agreed upon by the parties from time to time. The Credit Facility is subject to typical credit terms and certain event of default triggers, some of which may be satisfied by unencumbered assets of the Litigation Fund. The maturity date for the Credit Facility is July 31, 2025, and the interest rate under the Credit Facility is a variable rate plus a reference rate. The Global Fund has no potential encumbrances with respect to the Credit Facility. The Global Fund has entered into cash-settled swaps which represent economic exposure comparable to a notional interest in 1,812,709 Ordinary Shares (representing economic exposure comparable to approximately 1.5% of the outstanding Ordinary Shares) with Jefferies Financial Products, LLC and cash-settled swaps which represent economic exposure comparable to a notional interest in 740,988 Ordinary Shares (representing economic exposure comparable to approximately 0.6% of the outstanding Ordinary Shares) with Goldman Sachs International. Under the terms of the swaps, (i) the Global Fund will be obligated to pay to the counterparty any negative price performance of the specified notional number of Ordinary Shares subject to the swaps as of the expiration date of such swaps, plus interest rates set forth in the applicable contracts, and (ii) the counterparty will be obligated to pay the Global Fund any positive price performance of the specified notional number of Ordinary Shares subject to the swaps as of the expiration date of the swaps. All balances will be settled in cash. The swaps do not give the Reporting Persons or Funds direct or indirect voting, investment or dispositive control over any securities of the Issuer and do not require the counterparty thereto to acquire, hold, vote or dispose of any securities of the Issuer. Accordingly, the Reporting Persons disclaim any beneficial ownership of any Ordinary Shares that may be referenced in the swap contracts or Ordinary Shares or other securities or financial instruments that may be held from time to time by any counterparty to the contracts.
    Item 7.Material to be Filed as Exhibits.
     
    99.1 Transactions Effected by the Reporting Persons (on Behalf of the Funds) During the Past 60 Days.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Two Seas Capital LP
     
    Signature:/s/ Sina Toussi
    Name/Title:Sina Toussi/Managing Member of Two Seas Capital GP LLC, its general partner
    Date:05/22/2025
     
    Two Seas Capital GP LLC
     
    Signature:/s/ Sina Toussi
    Name/Title:Sina Toussi/Managing Member
    Date:05/22/2025
     
    Sina Toussi
     
    Signature:/s/ Sina Toussi
    Name/Title:Sina Toussi/Self
    Date:05/22/2025
    Get the next $INDV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INDV

    DatePrice TargetRatingAnalyst
    8/6/2025$27.00Buy
    H.C. Wainwright
    7/22/2025$20.00Buy
    Jefferies
    1/28/2025$16.00Buy
    Rodman & Renshaw
    7/23/2024$22.00Overweight
    Piper Sandler
    4/3/2024$37.00Buy
    Craig Hallum
    7/13/2023$35.00Outperform
    Northland Capital
    More analyst ratings

    $INDV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ

    RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. Live webcast link: https://edge.media-server.com/mmc/p/f78ufsat Par

    1/28/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Announces Completion of Redomiciliation to the United States

    RICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV), today announced completion of its redomiciliation from the United Kingdom to the United States. As a result, Indivior Pharmaceuticals, Inc., a new Delaware corporation ("IPI"), has become the new parent company. Indivior PLC is renamed Indivior Ltd. and has become a wholly-owned subsidiary of IPI. The common stock of Indivior Pharmaceuticals, Inc., is listed on Nasdaq and will continue to trade under the symbol "INDV."The last day of trading Indivior PLC ordinary shares on Nasdaq was January 23, 2026. Shareholders of Indivior PLC received one new IPI common share for each Indivior PLC ordinary sh

    1/26/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Provides Full-Year 2026 Financial Guidance and Business Update

    Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected in the Range of $430 million to $450 millionAdjusted EBITDA Expected in the Range of $535 million to $575 million RICHMOND, Va., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (NASDAQ:INDV) ("Indivior PLC" or the "Company") today announced its full-year 2026 financial guidance. "2025 was a transition year for Indivior in which we established the Indivior Action Agenda and completed Phase I – Generate Momentum – by growing U.S. SUBLOCADE net revenue, simplifying the organization and transform

    1/8/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Indivior with a new price target

    H.C. Wainwright initiated coverage of Indivior with a rating of Buy and set a new price target of $27.00

    8/6/25 8:01:45 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Indivior with a new price target

    Jefferies resumed coverage of Indivior with a rating of Buy and set a new price target of $20.00

    7/22/25 7:52:44 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Indivior with a new price target

    Rodman & Renshaw initiated coverage of Indivior with a rating of Buy and set a new price target of $16.00

    1/28/25 7:14:13 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    SEC Filings

    View All

    SEC Form 15-12G filed by Indivior PLC

    15-12G - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)

    1/26/26 4:10:43 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Indivior PLC

    S-8 - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)

    1/26/26 4:10:42 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Indivior PLC

    S-8 POS - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)

    1/26/26 4:04:19 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kingsley Stuart A was granted 3,722 shares, increasing direct ownership by 405% to 4,642 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    1/28/26 4:11:47 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wheadon David E. was granted 5,955 shares, increasing direct ownership by 41% to 20,350 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    1/28/26 4:10:57 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ryan Barbara was granted 3,722 shares, increasing direct ownership by 190% to 5,685 units (SEC Form 4)

    4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)

    1/28/26 4:10:09 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ryan Barbara bought $27,429 worth of Ordinary Shares (775 units at $35.39), increasing direct ownership by 65% to 1,963 units (SEC Form 4)

    4 - INDIVIOR PLC (0001625297) (Issuer)

    1/7/26 1:51:48 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Humphreys Keith bought $27,429 worth of Ordinary Shares (775 units at $35.39), increasing direct ownership by 15% to 5,802 units (SEC Form 4)

    4 - INDIVIOR PLC (0001625297) (Issuer)

    1/7/26 1:50:38 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ninivaggi Daniel A bought $27,429 worth of Ordinary Shares (775 units at $35.39), increasing direct ownership by 5% to 16,923 units (SEC Form 4)

    4 - INDIVIOR PLC (0001625297) (Issuer)

    1/7/26 1:49:33 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Leadership Updates

    Live Leadership Updates

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

    RICHMOND, Va., July 8, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Vanessa is a seasoned corporate affairs leader with extensive experience in the biopharmaceutical industry, and will be responsible for Corporate Communications, Government Affairs, Policy and Advocacy at Indivior. "We are excited to welcome Vanessa to the Indivior team," said Joe Ciaffoni, Chief Executive Officer. "Vanessa has an impressive track record of aligning teams to pr

    7/8/25 8:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Appoints Tony Kingsley to the Board of Directors

    RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, effective July 1, 2025. Mr. Kingsley was appointed pursuant to Indivior's relationship agreement with affiliates of Oaktree Capital Management, L.P., who supported his appointment. Tony Kingsley is an accomplished biopharmaceutical executive with a distinguished track record of building and leading organizations across multiple scientific disciplines, therapeutic areas, and stages of

    6/24/25 4:12:00 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Financials

    Live finance-specific insights

    View All

    Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ

    RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. Live webcast link: https://edge.media-server.com/mmc/p/f78ufsat Par

    1/28/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance

    Q3'25 Total Net Revenue of $314m, up 2% YOY; Q3'25 SUBLOCADE® Net Revenue of $219m, up 15% YOYAnnounces the Optimization of Rest of World (ROW) Business Discontinued the Sales and Marketing Support of OPVEE®Expect Annual Operating Expense Savings of at Least $150m in 2026On Track to Enter Phase II of the Indivior Action Agenda — Accelerate — January 1, 2026Conference Call Scheduled for Today at 8:00 A.M. EasternRICHMOND, Va., Oct. 30, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today reported its financial results for the third quarter ended September 30, 2025, and provided a business update.

    10/30/25 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th

    RICHMOND, Va., Oct. 16, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced that it will report its third quarter 2025 financial results on Thursday, October 30, 2025, at 7:00 a.m. U.S. ET. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. ET. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begi

    10/16/25 4:04:00 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Indivior PLC

    SC 13G - INDIVIOR PLC (0001625297) (Subject)

    11/15/24 6:03:54 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Indivior PLC

    SC 13G/A - INDIVIOR PLC (0001625297) (Subject)

    11/14/24 5:00:25 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Indivior PLC

    SC 13D/A - INDIVIOR PLC (0001625297) (Subject)

    11/7/24 8:23:16 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care